Radnor, PA. September 2, 2014 – ControlRad Systems, Inc., a medical device company developing innovative products to dramatically reduce radiation exposure and risk for patients and physicians performing fluoroscopic procedures, has secured long term funding to finalize development and launch of the Company’s lead product over the next few years. The deal is in addition to the previously announced financing rounds. Additional terms of the deal are confidential.
ControlRad Systems’ products are designed to deliver the right amount of radiation to the right spot at the right time. By closing the loop between an attention tracking device, such as an eye tracker, and a high speed “shutter,” or collimator, that directs the dose of radiation preferentially to the areas of greatest attention in real time, ControlRad Systems’ products have the potential to bring fluoroscopic radiation dose exposure into the 21st century. ControlRad Systems headquarters are in greater Philadelphia and its engineering development facilities are in Kfar Saba, Israel.
ControlRad is a privately-held medical technology company developing innovative products that dramatically reduce the lifetime risk of radiation exposure from fluoroscopically guided interventional procedures (FGIP) for patients and healthcare professionals. These products are designed to improve safety without compromising image quality or workflow. This is accomplished with an integrated set of proprietary components which optimize the X-ray beam to deliver optimal image quality in the clinically-relevant region of focus of the physician while maintaining appropriate resolution in the periphery. ControlRad is headquartered in Philadelphia and has engineering development facilities in Kfar Saba, Israel. For more information, visit www.controlrad.com.